Human Botulinum Neurotoxin A/B Immune Globulin
Brand Names: Babybig
Methodology & AI Transparency ⓘ
Human Botulinum Neurotoxin A/B Immune Globulin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: BabyBIG ® , Botulism Immune Globulin Intravenous (Human), is indicated for the treatment of infant botulism caused by toxin type A or B in patients below one year of age.
- 2 Real-world patient consensus: Zero-PHI community consensus: 84% favorable across 22 logged regimens (Babybig).
- 3 Typical cash cost range: Dispensing cost comparison spans $102.06 mail/discount cash up to $250.05 uninsured retail (federal NADAC $2.3100).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Human Botulinum Neurotoxin A/B Immune Globulin): nausea (12.7%), vomiting (6.3%), cutaneous rash (4.6%).
Ask our AI Specialists anything about Human Botulinum Neurotoxin A/B Immune Globulin
Human Botulinum Neurotoxin A/B Immune Globulin Mechanism, CYP450 Pathways & DailyMed Monograph
BabyBIG ® , Botulism Immune Globulin Intravenous (Human), is indicated for the treatment of infant botulism caused by toxin type A or B in patients below one year of age. BabyBIG is an immune globulin intravenous (human) indicated for: Treatment of infant botulism caused by toxin types A or B in patients below one year of age ( 1 ).
12.1 Mechanism of Action BabyBIG contains antibodies specific for botulinum neurotoxin types A and B that bind to and neutralize circulating toxin types A and B in the patient.
Following administration (50 mg/mL Injection, Powder, Lyophilized, for Solution), Human Botulinum Neurotoxin A/B Immune Globulin achieves Complete (~100%) parenteral systemic delivery for Human Botulinum Neurotoxin A/B Immune Globulin (50 mg/mL Injection, Powder, Lyophilized, for Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after human botulinum neurotoxin a/b immune globulin administration onset, governed by a Mean elimination half-life of 4 to 11 hours across adult Human Botulinum Neurotoxin A/B Immune Globulin dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of human botulinum neurotoxin a/b immune globulin.
Before initiating Human Botulinum Neurotoxin A/B Immune Globulin at 50 mg/mL Injection, Powder, Lyophilized, for Solution, clinical safety checklists rule out as with other immunoglobulin preparations, babybig should not be used in individuals with a prior history of severe reaction to other human immunoglobulin preparations.; contraindicated in patients with prior serious allergic response to human botulinum neurotoxin a/b immune globulin (ndc 68403-1100). Logged tolerability patterns center on nausea (12.7% of reports), headache (8.6% of reports), vomiting (6.3% of reports).
Reconcile eGFR-adjusted medications before escalating Human Botulinum Neurotoxin A/B Immune Globulin in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Human Botulinum Neurotoxin A/B Immune Globulin dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- As with other immunoglobulin preparations, BabyBIG should not be used in individuals with a prior history of severe reaction to other human immunoglobulin preparations.
- Contraindicated in patients with prior serious allergic response to Human Botulinum Neurotoxin A/B Immune Globulin (NDC 68403-1100)
Logged Side-Effect Incidence (22 Reports)
Human Botulinum Neurotoxin A/B Immune Globulin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Human Botulinum Neurotoxin A/B Immune Globulin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on [World Report] First human case of Shamonda virus A patient in France has died from the infection, which normally affects cattle. Virologists say the wider risk to public health is low. Marianne Guenot reports. The Lancet • 2026-10-31 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID LANCET-2806831375 ↗ |
| New Insights on Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized: What a 2,076-Participant Study Found These integrated analyses did not demonstrate any clinically meaningful impact from ADA occurring after treatment with eptinezumab. Frontiers in immunology • 2021-01-15 • Phase III Randomized Trial | N = 2,076 | 96/100 | PMID 34759933 ↗ |
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
| New Insights on LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is: What a 1,272-Participant Study Found LetibotulinumtoxinA significantly improved the psychosocial burden associated with glabellar lines across all trials. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2024-06-01 • Phase III Randomized Trial | N = 1,272 | 96/100 | PMID 38470985 ↗ |
| Can This Approach Help? Inside the Latest Research on CDC Issues Rabies Exposure The US Centers for Disease Control and Prevention (CDC) issued a health advisory in response to reports of increased human exposure to rabid or possibly rabid animals. JAMA Network • 2026-10-27 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 94/100 | PMID JAMA-3770029280 ↗ |
Human Botulinum Neurotoxin A/B Immune Globulin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.3100/unit (~$69.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $250.05 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $102.06 / mo | View logs ↓ |
Human Botulinum Neurotoxin A/B Immune Globulin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Human Botulinum Neurotoxin A/B Immune Globulin RxNorm Concept ID | 544491 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.3100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $250.05 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $102.06 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Human Botulinum Neurotoxin A/B Immune Globulin Patient Community, Cohort Filters & Dosage Logs
Deterministic Human Botulinum Neurotoxin A/B Immune Globulin reference combining NIH RxNorm (544491), Medicaid NADAC ($2.3100/unit), and anonymous cohort outcomes (84% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Human Botulinum Neurotoxin A/B Immune Globulin community threads and patient logs by age, biological sex, dosage, and treatment duration.